On Tuesday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported first-quarter adjusted earnings per share of $8.22, down 14% year-over-year, missing the consensus of $8.82. The company reported ...

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) released its Q1 2025 corporate presentation on April 29, 2025, highlighting continued growth of its flagship products amid evolving market dynamics.

Shares of Regeneron Pharmaceuticals Inc. declined Tuesday after the company tightened its forecast for sales of Eylea, an eye drug that brings in almost all of its revenue. Regeneron said U.S ...

Regeneron Pharmaceuticals on Monday announced plans to purchase genetic testing company 23andMe for $256 million. The New York-based drugmaker is set to take over 23andMe after winning a bankruptcy ...

The long-running “Du More” motif for Sanofi and Regeneron’s immunology blockbuster ... In the 60-second spot, “It's Possible: Water Slide, Groceries, Kites,” the Dupixent makers urge ...

Survey Most won't switch patients from Plavix. | Follow @MaureenFierce > The FDA has pushed back its review of Regeneron's Eylea for blindness by three months, a move that triggered a sharp 13% ...

Regeneron Q1 EPS fell 14% to $8.22, missing estimates; revenue dropped 4% to $3.03 billion, also below consensus. Eylea sales fell 26% to $1.04 billion amid pricing pressure and market share loss ...

On Tuesday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported first-quarter adjusted earnings per share of $8.22, down 14% year-over-year, missing the consensus of $8.82. The company reported sales ...